Prothena Corp. Valuation Multiples

Prothena Corp. Overview

About Prothena Corp.

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer’s disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Founded

2012

HQ

Employees

163

Website

prothena.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $31M

Net Income: ($174M)

EV

$270M

Valuation Multiples

Multiples.vc

Start free trial

Prothena Corp. Financials

Prothena Corp. reported last 12-month revenue of $31M.

In the same LTM period, Prothena Corp. generated $31M in gross profit and had net loss of ($174M).

Prothena Corp. P&L

In the most recent fiscal year, Prothena Corp. reported revenue of $10M and EBITDA of ($184M).

Prothena Corp. expects next 12-month revenue of XXX and NTM EBITDA of XXX

Prothena Corp. Stock Performance

Prothena Corp. has current market cap of $570M, and enterprise value of $270M.

Prothena Corp.'s stock price is $10.58.

Prothena Corp. Valuation Multiples

Prothena Corp. trades at 8.7x EV/Revenue multiple, and (1.5x) EV/EBITDA.

Prothena Corp. Financial Valuation Multiples

As of April 10, 2026, Prothena Corp. has market cap of $570M and EV of $270M.

Equity research analysts estimate Prothena Corp.'s 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Prothena Corp. has a P/E ratio of (3.3x).

Prothena Corp. Margins & Growth Rates

Prothena Corp.'s revenue in the last 12 month grew by 128%.

Prothena Corp.'s revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.2M for the same period.

Prothena Corp.'s rule of 40 is 808% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Prothena Corp.'s rule of X is 2019% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Prothena Corp. Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Prothena Corp. M&A Activity

Prothena Corp. acquired XXX companies to date.

Last acquisition by Prothena Corp. was on XXXXXXXX, XXXXX. Prothena Corp. acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Prothena Corp. Investment Activity

Prothena Corp. invested in XXX companies to date.

Prothena Corp. made its latest investment on XXXXXXXX, XXXXX. Prothena Corp. invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).